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ABSTRACT
Glioblastoma multiforme (GBM) is one of the most malignant brain tumors affecting
adults. It is characterized by necrotic tissue and abnormal vasculature, making it highly resistant
to current cancer treatments. A promising alternative to standard cancer therapeutics is the use of
drug delivery systems such as polymeric nanoparticles (NP) that deliver silencing RNA (siRNA)
exclusively to tumor cells for gene knockdown. Presently, nonviral delivery vectors, such as
poly(B-amino ester) (PBAE) NP, are beneficial delivery systems because they are less
immunogenic and easier to chemically modify than vectors delivered by viruses. Although
current formulations of PBAEs allow cargo release via hydrolytic degradation, the ideal delivery
vector should have an environmentally triggered siRNA release system to increase safety and
transfection efficacy. We hypothesized that the addition of disulfides to the main backbone of
PBAE NPs would reduce cytotoxicity and increase siRNA transfection efficacy. Glutathione, a
reducing agent present in the cytosol, can reduce a disulfide bond into two thiols and thus
increase NP degradability for safety and immediate siRNA release. In this study, we
characterized the binding, physical, and siRNA delivery properties of reducible PBAE NP.
Polymer-siRNA binding strength was analyzed by a gel retardation assay. NP size and zeta
potential were measured using NanoSight and zetasizer instruments, respectively. siRNA
transfection efficiency was assessed by the amount of green fluorescent protein detected in GBM
cells using a fluorescence plate reader. This study revealed that the addition of disulfide groups
to PBAEs increased their siRNA binding strength, lowered cytotoxicity, and increased siRNA
transfection efficiency. The best polymer showed 76% GFP knockdown while maintaining high
cell viability twenty days following transfection. This novel class of polymers can serve as

improved nonviral delivery vectors for a wide array of RNA interference (RNA1) targets,
including those associated with malignant tumors.

INTRODUCTION
Cancer is a leading cause of death worldwide and it is estimated that cancer mortality will
increase to exceed 11 million individuals in 2030.'* Current treatments include invasive surgery,
radiation therapy, and chemotherapy;>’ nevertheless these therapies sometimes exhibit high
toxicity and can cause deleterious side effects to patients undergoing treatment.’
Chemotherapy is currently the most effective treatment for tumors in the metastatic
stage.” It is a combinatorial drug therapy that targets rapidly proliferating cells by impeding
certain steps in the DNA replication process.” However, a critical issue in chemotherapy is the
lack of tumor selectivity and demise of healthy tissues during treatments.”’ Another challenge in
chemotherapy is multidrug resistance (MDR), which decreases the efficacy of anti-cancer drugs
for treatment.

MDR occurs when cancer cells become resistant to a broad range of anti-cancer

drugs after being exposed to one chemotherapeutic agent.’
A potential alternative to present cancer therapeutics is the use of nanoparticle-based drug
delivery systems, where nanoparticles can specifically target and deliver drugs to cancer cells,
while avoiding harm to normal cells. This targeting is facilitated by the enhanced permeability
and retention effect (EPR), a phenomenon that allows nanoparticles to actively or passively pass
through leaky tumor vasculature and aggregate at tumor sites.”’ Nanoparticles sized 50-200 nm
in diameter have been known to take advantage of the EPR phenomenon.’ Nanoparticles for drug
delivery are beneficial because of their scalability in production, increased intracellular stability,
and adjustable tissue specificity.

Currently, siRNA—based therapies present the following barriers: quick systemic
clearance, low cellular uptake, and obliteration by nucleases.'” However, polymeric nanoparticles
have been known to show advantageous qualities for siRNA delivery because they can be easily
chemically modified and can provide protection for siRNA from serum nuclease degradation.’
Nanoparticles can be used to deliver silencing RNA (siRNA) exclusively to cancer cells to
silence genes associated with tumorigenesis in a therapeutic process called RNA interference
(RNAi).

Once in the cytoplasm, siRNA can induce the degradation of its homologous messenger

RNA target, therefore inhibiting the synthesis of a protein.’
Presently, viral delivery vectors have high transfection efficiency, because of their natural
ability to efficiently insert genetic cargo into cells.” They can also easily condense nucleic acids,
making their transportation to the cytoplasm easier.'' Nevertheless, they exhibit potential
mutagenesis, high immunogenicity, small cargo capacity, and are difficult for chemical
modification.’ Due to these immunological toxicities, no therapeutic treatments have been
approved into the market.'” Alternatively, non-viral delivery vehicles display advantageous
attributes, such as lower cytotoxicity, reduced immunogenicity, large cargo capacity, and
feasibility in large scale production, but lack high transfection efficacy.’
Cationic polymers for siRNA delivery are most effective for gene therapy when the
following factors are accomplished effectively.

Polymer-siRNA binding must be strong to

prevent dissociation or degradation of the polymer/siRNA complex.

Binding is possible through

the electrostatic attraction between cationically charged amine groups on a polymer and anionic
siRNA. The cationic charge on a nanoparticle is also important for endocytotic cellular uptake
because it should be cationic enough to become attracted to the negatively charged proteoglycans
found on the phospholipid membrane surface.

After endocytosis, the nanoparticle needs to

successfully escape the endosome to avoid becoming degraded by the acidifying environment of
a lysosome.
A major cause of low transfection efficacy has been known to be the inefficient escape of
the polymer/siRNA complex from the endosome.'® Therefore, the secondary and tertiary amines
on the polymer structure serve as a buffering system that induces osmotic swelling and
endosomal lysis, this process is known as the proton sponge effect.
complex to make its way into the cytoplasm safely.

It allows the polymer-siRNA

Now to release the siRNA from the

polymer/siRNA complex, the polymer’s acrylate bonds are cleaved by water molecules in the
cytoplasm and the polymer degrades to reduce the possibility of cytotoxicity.’
Linear cationic polymers have the ability to bind and condense nucleic acids, such as
siRNA into stable nanoparticles.'® Biodegradable cationic poly(B-amino esters) (PBAEs)
nanoparticles are attractive non-viral delivery vectors because of several characteristics.

They

have an efficient buffering system that allows endosomal escape, an ability to bind siRNA into a
stable nanoparticle/siRNA complex, increased transfection efficiency, reduced cytotoxicity, and
improved biodegradability.” PBAEs are formed through a Michael addition of diacrylates to
primary or bis-secondary amines.® Small modifications to a polymer’s chemical structure with
varying end groups can cause large changes to its size and so they are chemically modified."
We hypothesized that the addition of disulfides to the main backbone of PBAE NPs
would reduce cytotoxicity and increase siRNA transfection efficacy.

Glutathione found in high

concentrations of about 1-8mM in the cell cytoplasm versus 5-50uM in blood serum can serve as
a reducing agent to reduce a disulfide bond into two thiols."

This can degrade the nanoparticle

allowing the siRNA to dissociate and induce the obliteration of its homologous mRNA.

We seek

to discover the best siRNA/polymer formulation that achieves the highest siRNA transfection
efficacy and lowest cytotoxicity in Glioblastoma 319 cells. This study aims to characterize the
binding, physical, and siRNA delivery properties of bioreducible poly (B-amino ester)
nanoparticles with disulfide linkages.
MATERIALS AND METHODS
Polymers
Small aliquots of ten polymers at 100 mg/mL in dimethyl sulfoxide (DMSO) plus
dessicant were stored at 4°C.

Glioblastoma cell cultures

Glioblastoma (GB) astrocyte cells were cultured in Dulbecco’s Modified Eagle Medium
(DMEM

11995, Invitrogen, Carlsbad CA) with 10% Fetal Bovine Serum (FBS) and 1% anti-anti.

Cells were kept in an incubator sustaining a humid 5% CO2 atmosphere at 37°C.

Cells had their

media removed and resupplied with fresh media every Monday, Wednesday, and Friday for nine
weeks.

Nanoparticle Sizing and Zeta Potential Analysis
A NanoSight NS500 instrument (NanoSight Ltd. Wiltshire, UK) was used to size
nanoparticles.

A triplicate of each polymer sample was performed.

Both polymer and scRNA

concentrations were diluted in sodium acetate. Additionally, each scRNA/polymer solution was
diluted 1:100 in phosphate buffered saline (PBS). A Zetasizer Nanoseries Nano-ZS90 was used to
measure nanoparticle zeta potential.

Both polymer and scRNA were diluted in sodium acetate

buffer. Each diluted solution was mixed and left to incubate for 10 minutes for particle formation.

Then 200 pl of particle/scRNA solution was diluted in 800 ul of PBS.

After, a diluted particle

solution was injected into a zeta cell and placed in the Zetasizer apparatus for analysis.
Polymer-siRNA binding study: Gel Retardation Assay
Polymer concentrations ranging from 0-600 w/w were diluted in different concentrations
of sodium acetate buffer. Then a constant concentration of scrambled RNA (scRNA) was diluted
in a constant concentration of sodium acetate. After, the diluted polymer solution was mixed with
the diluted scRNA solution and left to incubate for ten minutes for particle formation.

The loading

buffer was 30% water diluted glycerol with no dye. This loading buffer was added to the
polymer/scRNA particles in the first row of wells.
polymer/scRNA binding, dyes were excluded.

To prevent any interference with

To observe the reducing action of glutathione on a

particle disulfide bond, SmM glutathione was added to the polymer/scRNA particles in the second
row of wells. Particle samples from both wells were loaded into a 1% agarose gel with ethidium
bromide staining. Gel ran for 20 minutes at 100 V and was exposed to UV to see the bands.
siRNA Transfection and Cell Viability Assay
Cells were plated in 96-well tissue culture treated plates at a concentration of 15,000 cells
per well. DMEM was added to all wells and plates were placed in the incubator at 37°C overnight.
Lipofectamine 2000 (Invitrogen) was mixed with Optimem I (Invitrogen) following specific
directions from the manufacturer’s protocol. Lipofectamine served as a positive control for the
transfection experiment.

Then siRNA and scRNA were both diluted in sodium acetate and

pipetted into a 96-well round bottom plate. Polymers were also diluted in sodium acetate and
aliquoted out into the same 96-well round bottom plate. Polymer solutions were then mixed with
the scRNA solutions on one row and siRNA solutions on another row. Particle solutions incubated

for ten minutes for particle formation and then were added to GB cells. After transfection, plates
were placed in incubator for four hours, followed by a removal of media and a resupply of fresh
DMEM.

Cell viability was examined by the CellTiter 96 AQeous One MTS assay (Promega).

Media was removed from cells and cell titer reagent was added to transfected cells and incubated
for one hour. Cells with only media and no nanoparticle/siRNA/scRNA solution (control) were
normalized.

GFP knockdown in transfected cells was monitored for 20 days by a measuring

absorbance of each well using a BioTek Synergy 2 plate reader.

Statistical Treatment of Data

GraphPad Prism 5 software was used for all statistical analysis.
graphs indicate +/- standard error of mean.
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Figure 3. Gel retardation assay of R637,
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Discussion

Of the non toxic polymers, the best polymer for siRNA transfection was BR6-S3-E7
(with a 1:1 ratio of B6 and BR6 polymer and 20nM siRNA and 600wt/wt polymer mix) showing a
76% GFP knockdown and exhibiting a 3.6% percent loss in metabolic activity in cells, twenty days
following transfection (Figure 4). The BR6-S4-E7 polymer (with a 1:1 ratio of B6 and BR6
polymer and 20 nM siRNA and 600wt/wt polymer mix) also showed a 76% GFP knockdown but
exhibited a 30 % percent loss in metabolic activity (Figure 4). These data suggesting that a
balanced ratio of 1:1 of BR6 and B6 polymers worked best at achieving a higher transfection
efficiency and high cell viability. Both non reducible polymers that lacked disulfide bonds, 637
and 647 showed a 97-100% GFP knockdown, but exhibited a 96-97% percent loss in metabolic
activity in cells (Figure 4). Polymers 637 and 647 were too toxic to be potentially used
therapeutically.

The high cytotoxicity may have resulted from the lack of reducible disulfide

bonds and thus decreased biodegradability.
Average nanoparticle mean diameter between all ten polymers was approximately 130160 nanometers (Figure 1). Average nanoparticle zeta potential ranged from 6-24 millivolts,
majority of them being cationic (Figure 2). Other studies state that zeta potentials greater than
ten millivolts are required for PBAE nanoparticle transfection (Sunshine, Peng, Green 2012).
Gel retardation assays showed that in the presence of SmM glutathione, the disulfide bonds of
the R637 and R647 polymers were reduced and siRNA was released at all ranges of 0 to 600
polymer/siRNA w/w.

However, the 637 and 647 polymers that lacked disulfide bonds did not

release siRNA in the presence of SmM glutathione at any polymer/siRNA w/w range (Figure 3).
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This study revealed that the addition of disulfide groups to PBAEs increased their siRNA
binding strength, lowered cytotoxicity, and increased siRNA transfection efficiency. PBAE
nanoparticle polymers can serve as efficient nonviral delivery vehicles for different RNA
interference (RNAI) targets, because of their increased biodegradability and efficient siRNA
transfecting abilities. This novel class of polymeric nanoparticles can serve as improved
nonviral delivery vectors for a wide array of RNA interference (RNAI) targets, including those
associated with malignant tumors.
Future Directions

Future directions include the optimization of the siRNA transfection study. The goal is to
achieve both a high green fluorescent protein knockdown and cell viability following a
transfection. We also plan to conduct a transfection in a xenograft mouse model using the 1:1
BR6 polymer-siRNA mixture (polymer with disulfide bonds) and measure the amount of
fluorescence detected.
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